Hostname: page-component-8448b6f56d-qsmjn Total loading time: 0 Render date: 2024-04-19T16:47:54.241Z Has data issue: false hasContentIssue false

Economic impact of dementia in developing countries: an evaluation of costs of Alzheimer-type dementia in Argentina

Published online by Cambridge University Press:  27 July 2006

Ricardo F. Allegri
Affiliation:
Department of Neuropsychiatry, CEMIC University, Buenos Aires, Argentina Memory Research Center, Department of Neurology, Zubizarreta General Hospital, Buenos Aires, Argentina
Judith Butman
Affiliation:
Memory Research Center, Department of Neurology, Zubizarreta General Hospital, Buenos Aires, Argentina
Raúl L. Arizaga
Affiliation:
Memory Research Center, Department of Neurology, Zubizarreta General Hospital, Buenos Aires, Argentina
Gerardo Machnicki
Affiliation:
Novartis Argentina
Cecilia Serrano
Affiliation:
Department of Neuropsychiatry, CEMIC University, Buenos Aires, Argentina Memory Research Center, Department of Neurology, Zubizarreta General Hospital, Buenos Aires, Argentina
Fernando E. Taragano
Affiliation:
Department of Neuropsychiatry, CEMIC University, Buenos Aires, Argentina “Nuestra Sra de las Nieves” Nursing Home, Buenos Aires, Argentina
Diego Sarasola
Affiliation:
Department of Neuropsychiatry, CEMIC University, Buenos Aires, Argentina
Leandro Lon
Affiliation:
Department of Neuropsychiatry, CEMIC University, Buenos Aires, Argentina Memory Research Center, Department of Neurology, Zubizarreta General Hospital, Buenos Aires, Argentina “Nuestra Sra de las Nieves” Nursing Home, Buenos Aires, Argentina

Abstract

Background: There is no previous information about economic costs of Alzheimer's disease (AD) in South America. The objective of this study was to evaluate the costs of AD in Argentina.

Methods: Eighty community-dwelling patients, 20 institutionalized AD patients and their respective primary caregivers, and 25 healthy elderly subjects participated in this study. The cognitive and neuropsychiatric impairments and severity of dementia were assessed with the Mini-mental State Examination, Neuropsychiatric Inventory and Clinical Dementia Rating, respectively. A structured interview about health and health-care resources used during the past 3 months was administered to family caregivers. The time devoted by carers to looking after the patients and the caregiver burden (Zarit's Burden Interview) were recorded.

Results: The annual direct costs of the disease increased with cognitive deterioration from US$3420.40 in mild to US$9657.60 in severe AD, and with institutionalization (US$3189.20 outpatient vs. US$14 447.68 institutionalized). Most direct costs were paid for by the family.

Conclusions: With the projected increase in the number of persons at risk for developing AD in emerging countries, the family cost of the disease will be significant. Dementia costs should be a matter of analysis when health policies are being designed in developing countries.

Type
Research Article
Copyright
International Psychogeriatric Association 2006

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)